Measles vaccine potency and Sero- conversion rates among infants receiving measles immunization in Ilorin, Kwara state, Nigeria.

dc.contributor.authorFowotade, A.
dc.contributor.authorOkonko, I. O.
dc.contributor.authorNwabuisi, C.
dc.contributor.authorBakare, R. A.
dc.contributor.authorFadeyi, A.
dc.contributor.authorAdu, F. D.
dc.date.accessioned2026-02-27T13:42:09Z
dc.date.issued2014
dc.description.abstractThis study was designed to assess the seroconversion rate of measles vaccine among infants receiving measles immunization in Ilorin, Nigeria. The pre- and post-measles vaccination sera of the children were tested using the Haemagglutination Inhibition test. The measles vaccines administered at the immunization centre were also tested for their potency using in-vitro titration method. Only 286 (71.5%) of the vacinees returned to give post-vaccination samples. All the infants screened had low pre-vaccination measles antibody titers. Thirty one (8.0%) of the infants had measles prior to vaccination. The seroconversion pattern showed that 196 (68.6%) of the infants developed protective antibody titers. Low seroconversion rate reported in this study was due to low vaccine potency. The titers of vaccines with low potency ranged between log10−1.0–log10−2.25 TCID/per dose. This was beside other non specific antiviral substances exhibited virus neutralizing activity. Only 3 (50%) of the 6 vaccine vials tested had virus titers of log10−3.25 to log10−3.5, which fell above the cut-off point recommended by the World Health Organization for measles vaccines. The sero-conversion rate of 68.6% observed among vaccinees is far lower than the immunity level of 95% required stopping measles transmission in an endemic community. Failure of 31.4% of these infants to sero-convert post vaccination can be attributed partly to administration of sub-potent vaccines. There is need for improvement and maintenance of effective vaccine cold chain system in Nigeria. There is need also for periodic monitoring of post-vaccination antibody titers as well as vaccine potency status in order to ensure development of protective seroconversion rates.
dc.identifier.issn1532-1819
dc.identifier.issn1532-4230
dc.identifier.otherui_art_fowotade_measles_2015
dc.identifier.otherJournal of Immunoassay and Immunochemistry, 36(2), pp. 195–209
dc.identifier.urihttps://repository.ui.edu.ng/handle/123456789/12703
dc.language.isoen
dc.publisherTaylor & Francis
dc.subjectmeasles vaccine
dc.subjectsero-conversion
dc.subjectdeveloping countries
dc.subjectpotency
dc.subjectinfants
dc.subjectimmunization
dc.subjectNigeria
dc.titleMeasles vaccine potency and Sero- conversion rates among infants receiving measles immunization in Ilorin, Kwara state, Nigeria.
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
(24) ui_art_fowotade_measles_2015.pdf
Size:
110.48 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description: